


FTIDC

Cat. No.:	HY-100405
CAS No.:	873551-53-2
Molecular Formula:	C ₁₈ H ₂₃ FN ₆ O
Molecular Weight:	358.41
Target:	mGluR
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	FTIDC is an orally active, noncompetitive, selective allosteric metabotropic glutamate receptor (mGluR) 1 antagonist with an IC ₅₀ of 5.8 nM for human mGluR1a. FTIDC has no species differences in its antagonistic activity on recombinant human, mouse, and rat mGluR1 ^[1] .									
IC₅₀ & Target	mGluR1a 5.8 nM (IC ₅₀)	mGlu ₅ 6200 nM (IC ₅₀)								
In Vitro	FTIDC inhibits L-glutamate-induced increases in intracellular Ca ²⁺ concentrations, with IC ₅₀ values of 5.8 nM, 5.8 nM, 3.1 nM, 7.7 nM for human mGluR1a, rat mGluR1a, mouse mGluR1a, human mGluR1b in CHO cells, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.									
In Vivo	<p>FTIDC (i.p. or p.o.; 1-30 mg/kg) reduces the duration of face-washing behavior elicited in a dosedependent manner and the inhibitory effect is statistically significant at 10 and 30 mg/kg with i.p. and 30 mg/kg with p.o.^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male CD1 (ICR) mice of 6-weeks-old^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1, 3, 10, and 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p. or p.o.</td> </tr> <tr> <td>Result:</td> <td>Reduced the duration of face-washing behavior elicited in a dosedependent manner and was statistically significant at 10 and 30 mg/kg with i.p. and 30 mg/kg with p.o..</td> </tr> </table>		Animal Model:	Male CD1 (ICR) mice of 6-weeks-old ^[1]	Dosage:	1, 3, 10, and 30 mg/kg	Administration:	i.p. or p.o.	Result:	Reduced the duration of face-washing behavior elicited in a dosedependent manner and was statistically significant at 10 and 30 mg/kg with i.p. and 30 mg/kg with p.o..
Animal Model:	Male CD1 (ICR) mice of 6-weeks-old ^[1]									
Dosage:	1, 3, 10, and 30 mg/kg									
Administration:	i.p. or p.o.									
Result:	Reduced the duration of face-washing behavior elicited in a dosedependent manner and was statistically significant at 10 and 30 mg/kg with i.p. and 30 mg/kg with p.o..									

REFERENCES

[1]. Suzuki G, et al. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA